AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the FDA for Priority Review. This application, based on the positive ADRIATIC Phase III trial results in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease…
Commonwealth Care Alliance (CCA) has expanded its provider agreement with Beth Israel Lahey Health (BILH) to enhance care access for its Senior Care Options (SCO) and One Care members. This expanded network will serve approximately 20 towns and cities in…
Trilliant Health, a top analytics firm in the healthcare sector, has introduced a free version of its Provider Directory application. This user-friendly tool offers a centralized source for precise and up-to-date information on millions of healthcare providers and is now…
Alpenglow Biosciences, a pioneer in 3D spatial biology, has recently received contracts from the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH). Additionally, the company has secured further investment to advance the development of…
Success Beyond Game Day and SHREDmill have partnered to integrate AI-driven mindset training into XPE’s SHREDmill platform and online community. This collaboration seeks to elevate the overall development of athletes by incorporating advanced mental training into their speed training programs,…
Universal DX (UDX) has completed its Series B funding round, which will support the clinical trial for its colorectal cancer screening blood test, Signal-C®. This trial is a key step toward securing FDA premarket approval and advancing the company’s mission…
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on utilizing patients’ own biology to treat rare diseases, has announced the online publication of data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial in…
Concentra®, a leading provider of occupational medicine, has announced the introduction of its new behavioral health service on Concentra Telemed®, the company’s telemedicine platform for workers’ compensation. Concentra® has introduced a behavioral health service to its Concentra Telemed® platform, enhancing…
Ontrak, Inc. (NASDAQ: OTRK), a top AI-driven and telehealth-enabled behavioral healthcare company, has earned HITRUST Risk-based, 2-year (r2) certification for the customer data exchange components of its Ontrak Advanced Engagement System. This certification highlights Ontrak’s steadfast dedication to upholding the…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for the on-demand treatment of hereditary angioedema (HAE). The application will…
Francisco Partners, a global investment firm specializing in technology and healthcare, has announced the sale of QGenda to Hearst. Financial terms of the deal were not disclosed. QGenda, a leader in healthcare workforce management, serves over 700,000 providers across 45…
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet regimen of venetoclax and azacitidine for newly diagnosed, unfit AML…